Given that multiple previous reports have shown dysregulated cell cycle gene expression within the known CDKN2A/Cyclin D1-CDK4-CDK6/Rb axis, CDK4/6 inhibition represents a promising approach in ovarian cancer. Here, RB1 is linked to ovarian carcinoma.